Last updated: September 24, 2026
Aprocitentan is an oral dual endothelin receptor antagonist commercialized in the United States as Tryvio by Johnson & Johnson’s Janssen Pharmaceuticals. The FDA approved Tryvio in March 2024 for adults with hypertension whose blood pressure is not adequately controlled with other antihypertensive drugs. The product targets resistant hypertension, a clinically important but commercially competitive segment. Its initial opportunity is constrained by a required REMS program, embryo-fetal toxicity warnings, an add-on treatment position, and competition from inexpensive generic therapies.
No product-level Tryvio revenue was separately reported by Johnson & Johnson in the company’s 2024 public financial reporting. The near-term commercial case therefore depends on formulary access, specialist adoption, Medicare and commercial reimbursement, and the ability to identify patients with resistant hypertension who remain uncontrolled despite multidrug therapy.
What is aprocitentan and how does Tryvio work?
Aprocitentan blocks both endothelin A and endothelin B receptors. Endothelin-1 is a potent vasoconstrictor involved in vascular resistance and hypertension. Aprocitentan is designed to reduce endothelin-mediated vasoconstriction and sodium-retaining effects through dual receptor blockade.
Tryvio is supplied as a 12.5 mg tablet taken once daily. The approved indication is narrower than treatment of general hypertension:
- Adults with hypertension
- Blood pressure not adequately controlled with other antihypertensive drugs
- Use as an add-on therapy
- Distribution subject to the Tryvio REMS because of embryo-fetal toxicity risk
The product’s approved dose is 12.5 mg once daily. In the PRECISION clinical program, aprocitentan produced sustained reductions in systolic blood pressure in patients whose hypertension remained uncontrolled despite multiple medications (FDA, 2024).
What clinical evidence supports aprocitentan?
The principal commercial evidence comes from the phase 3 PRECISION trial. The study enrolled patients with resistant hypertension and evaluated aprocitentan against placebo during an initial treatment period, followed by longer-term treatment.
The product’s clinical advantages are:
- A differentiated mechanism from renin-angiotensin, calcium-channel, beta-blocker, and diuretic therapies.
- Demonstrated blood-pressure reduction in patients already receiving several antihypertensive agents.
- Once-daily oral dosing.
- A treatment position in a population with substantial residual medical need.
The main limitations are edema and fluid retention, which are class effects of endothelin receptor antagonists. The FDA label also identifies anemia and embryo-fetal toxicity as important safety concerns. These factors limit broad primary-care use and make monitoring and patient selection central to adoption (FDA, 2024).
When did Tryvio receive FDA approval and lose exclusivity?
Tryvio received FDA approval in March 2024. The approval did not create a broad first-line hypertension product. It placed aprocitentan in the later-line, resistant-hypertension segment.
| Milestone |
Date or status |
| FDA approval |
March 2024 |
| Brand |
Tryvio |
| Active ingredient |
Aprocitentan |
| Dose |
12.5 mg once daily |
| Indication |
Add-on treatment for uncontrolled hypertension |
| Distribution restriction |
Tryvio REMS |
| Launch market |
United States |
| Product-level revenue disclosure |
Not separately reported by Johnson & Johnson in 2024 public reporting |
The effective loss-of-exclusivity date cannot be reduced to a single public date without accounting for the complete U.S. patent estate, Orange Book listings, pediatric exclusivity, patent-term adjustment, and any litigation outcome. Aprocitentan’s commercial protection is likely to depend on a combination of compound, formulation, and method-of-use rights rather than regulatory exclusivity alone.
The FDA approval itself does not establish a long period of market exclusivity comparable to a new chemical entity with a clean 12-year biologic exclusivity period. Aprocitentan is a small molecule, so generic competition can ultimately proceed through an abbreviated new drug application once relevant patents and regulatory exclusivities no longer block approval.
What patents protect aprocitentan and Tryvio?
Aprocitentan originated from the Actelion drug-discovery portfolio and is now linked commercially to Idorsia and Janssen. Public patent protection has historically covered the endothelin receptor antagonist chemical series, pharmaceutical compositions, and therapeutic use.
The commercially relevant patent categories are:
| Patent category |
Commercial function |
| Compound patents |
Protect aprocitentan or closely defined chemical structures |
| Salt and crystal-form patents |
Protect solid-state forms used in drug manufacture |
| Formulation patents |
Protect tablet composition, stability, or release characteristics |
| Method-of-use patents |
Protect treatment of resistant or difficult-to-control hypertension |
| Manufacturing patents |
Protect intermediates, synthesis routes, or process controls |
The strongest protection is generally the valid compound patent. Formulation and method-of-use patents can delay or complicate generic entry but may not prevent a generic applicant from designing around the claimed formulation or omitting a patented indication.
How strong is the aprocitentan patent estate?
The estate has meaningful commercial value because aprocitentan is a differentiated small-molecule therapy with a defined resistant-hypertension indication. Its strength is reduced by four factors:
- Generic applicants can challenge small-molecule patents through the ANDA Paragraph IV process.
- The approved treatment population is narrower than the overall hypertension market.
- Method-of-use claims may be vulnerable to carve-out strategies.
- The product must compete with low-cost generic antihypertensives even before direct generic entry.
An Orange Book assessment should focus on the currently listed U.S. patents for Tryvio, their expiration dates, pediatric exclusivity, patent-term adjustment, and any litigation under the Hatch-Waxman framework. Public commercial materials do not establish a reliable standalone revenue forecast from patent life alone.
What is the Orange Book status of Tryvio?
Tryvio is an FDA-approved small-molecule drug and is therefore eligible for Orange Book patent listing. The Orange Book is the central source for determining which patents FDA considers to be associated with the approved product and which patents an ANDA applicant may challenge.
The relevant legal questions are:
- Which patents are listed against the 12.5 mg tablet?
- Which claims cover the approved use rather than an unapproved use?
- Are any listed patents still within their enforceable term?
- Has an ANDA applicant submitted a Paragraph IV certification?
- Has Janssen or an affiliated patent owner filed suit within 45 days?
- Is a settlement agreement subject to FTC review or public disclosure?
No widely reported Paragraph IV litigation involving aprocitentan was established in the public record available for this analysis through the 2024 commercial launch period. That status can change as the product gains sales and generic manufacturers assess the market.
Which companies are challenging aprocitentan?
No major publicly reported generic challenger had established a commercial launch position against Tryvio during the initial U.S. launch period.
Potential challengers include large generic manufacturers with hypertension portfolios, such as Teva, Viatris, Sandoz, Sun Pharma, Lupin, and Dr. Reddy’s Laboratories. The likely entry route is an ANDA rather than a 505(b)(2) application because the reference product is an oral small molecule with an established tablet dosage form.
A generic challenger would assess:
- Compound-patent validity and expiration.
- Whether the approved indication can be carved out.
- The commercial value of the resistant-hypertension population.
- REMS obligations and whether a shared system is required.
- Manufacturing complexity and supply economics.
- The likelihood of settlement before launch.
The absence of an early challenge would not necessarily indicate a strong patent estate. It may reflect the limited size of the initial market, the cost of development, or uncertainty about reimbursement.
What market does aprocitentan target?
Aprocitentan targets resistant hypertension, generally understood as blood pressure that remains above goal despite treatment with multiple antihypertensive agents, including a diuretic in typical clinical definitions.
The addressable market has two layers:
| Market layer |
Commercial relevance |
| Overall hypertension |
Very large, but dominated by generic drugs and unsuitable for premium pricing |
| Resistant hypertension |
Smaller, more specialist-driven, and more suitable for differentiated therapy |
The product’s commercial opportunity is shaped by the gap between epidemiologic prevalence and treated demand. Many patients with apparent resistant hypertension have pseudo-resistance caused by poor adherence, inaccurate measurement, secondary hypertension, excess sodium intake, drug interactions, or inadequate diuretic selection. Physicians may therefore reserve Tryvio for carefully evaluated patients.
Aprocitentan also competes with established off-label or later-line strategies, including intensified diuretic therapy, mineralocorticoid receptor antagonists, device-based approaches, and other vasodilator regimens. Spironolactone is especially important because it is inexpensive and has strong clinical familiarity in resistant hypertension.
How does aprocitentan compare with other hypertension drugs?
| Attribute |
Aprocitentan |
Spironolactone |
Standard generic antihypertensives |
| Mechanism |
Dual endothelin A/B blockade |
Mineralocorticoid receptor antagonism |
Multiple mechanisms |
| Typical role |
Add-on treatment for resistant hypertension |
Common resistant-hypertension add-on |
First-line and combination therapy |
| Cost position |
Branded premium |
Generic low cost |
Generic low cost |
| Key safety concern |
Edema, fluid retention, anemia, embryo-fetal toxicity |
Hyperkalemia, endocrine effects |
Class-dependent |
| Distribution controls |
Tryvio REMS |
None comparable |
Usually none |
| Commercial differentiation |
Novel mechanism |
Strong clinical familiarity |
Broad access and low price |
Tryvio must demonstrate value beyond additional blood-pressure reduction. Payers will likely demand evidence that the product reduces cardiovascular events, hospitalization, or treatment burden, although the FDA approval was based on blood-pressure outcomes rather than a completed cardiovascular-outcomes program.
What is the financial trajectory for Tryvio and Idorsia?
Tryvio is strategically important to Idorsia because Idorsia has retained an economic interest in the product while relying on Janssen for major-market development and commercialization. The partnership reduces Idorsia’s commercial infrastructure requirements but also limits its direct control over U.S. pricing, sales execution, and launch investment.
Johnson & Johnson has not reported Tryvio as a standalone material revenue line in its public financial disclosures through the initial launch period. The product’s early revenue trajectory is therefore likely to be gradual rather than immediately material at the group level.
Base-case revenue drivers
The base case depends on:
- Slow specialist-led uptake
- Prior authorization and step-therapy requirements
- Concentration in patients failing several generic drugs
- Limited primary-care prescribing
- Moderate persistence if blood-pressure control is sustained
- A premium price constrained by inexpensive alternatives
Upside drivers
Upside would require:
- Strong real-world evidence in resistant hypertension
- Favorable Medicare and commercial formulary placement
- Broader recognition of endothelin biology in hypertension
- Expansion into additional cardiovascular or renal indications
- Clinical data showing benefits beyond blood-pressure lowering
- Successful international approvals
Downside drivers
Downside risks include:
- Persistent edema and fluid-retention concerns
- REMS-related prescribing friction
- Generic spironolactone and other low-cost alternatives
- Narrow diagnosis and under-recognition of true resistant hypertension
- Lack of cardiovascular-outcomes evidence
- Early Paragraph IV challenges
- Weak payer willingness to reimburse a premium add-on therapy
What licensing deals support aprocitentan?
Idorsia and Janssen entered a global development and commercialization arrangement for aprocitentan. The transaction gave Janssen responsibility for late-stage development and commercialization in major markets, while Idorsia retained an economic interest in the program. The agreement is strategically significant because it transferred late-stage execution to a company with established cardiovascular commercialization capabilities.
The financial terms and milestone structure have not produced a publicly reported product-level revenue stream that allows an independent calculation of Tryvio’s contribution to either company. Idorsia’s financial trajectory is therefore influenced by milestone receipts, royalties, development costs, and the timing of commercial sales rather than by reported net sales alone (Idorsia, 2024).
What generic launch risks exist for aprocitentan?
A generic launch is most likely to occur through one of three scenarios:
- Patent expiry without litigation.
- A Paragraph IV challenge followed by settlement and an agreed launch date.
- Litigation loss or patent invalidation, allowing earlier entry.
The most commercially realistic first-entry product would be an aprocitentan tablet with the same strength and bioequivalence profile. The generic manufacturer would still face a smaller market than suppliers of amlodipine, losartan, lisinopril, or hydrochlorothiazide.
The REMS may create operational complexity, but it is unlikely to be a durable barrier if FDA permits an equivalent generic distribution arrangement. Manufacturing barriers may have greater practical importance if synthesis requires specialized intermediates or if the active pharmaceutical ingredient has limited supplier capacity.
What regulatory and geographic markets matter?
The United States is the lead commercial market because Tryvio received FDA approval there. The European Union, Japan, and other major markets represent potential expansion opportunities but require separate regulatory decisions, pricing negotiations, and local commercialization arrangements.
Geographic growth is likely to vary:
- United States: first launch and highest near-term commercial visibility
- European Union: potential opportunity, but national reimbursement negotiations will determine access
- Japan: potentially distinct commercial rights and regulatory strategy
- Emerging markets: lower pricing and greater generic substitution pressure
A broader regulatory footprint would improve manufacturing scale and support clinical development in chronic kidney disease, pulmonary vascular disease, or other endothelin-linked conditions. Those opportunities remain dependent on clinical evidence and regulatory strategy.
Key Takeaways
- Aprocitentan, marketed as Tryvio, is a differentiated oral dual endothelin receptor antagonist for add-on treatment of resistant hypertension.
- FDA approval came in March 2024, with a 12.5 mg once-daily dose and a REMS requirement.
- The commercial market is smaller than the overall hypertension market and is dominated by specialist treatment of patients uncontrolled on multiple drugs.
- Johnson & Johnson did not separately report material Tryvio revenue in its 2024 public financial reporting.
- Idorsia’s financial exposure is tied to the Janssen partnership, milestones, royalties, and commercial uptake.
- The principal commercial threats are generic low-cost alternatives, edema and fluid-retention concerns, reimbursement restrictions, and future Paragraph IV activity.
- The patent estate may provide meaningful protection, but compound, formulation, method-of-use, and manufacturing rights should be analyzed separately.
- No major publicly reported generic challenger had established a commercial launch position during the initial U.S. launch period.
FAQs
Is aprocitentan a first-line blood-pressure medicine?
No. Tryvio is approved as add-on treatment for adults whose hypertension remains uncontrolled with other antihypertensive drugs.
Does aprocitentan have a biosimilar risk?
No. Aprocitentan is a small-molecule drug, so the relevant future competition is generic ANDA competition rather than biosimilar competition.
Why does Tryvio require a REMS?
The FDA requires the REMS because aprocitentan can cause embryo-fetal toxicity. The program is designed to control exposure during pregnancy and support safe prescribing and dispensing.
Is aprocitentan commercially superior to spironolactone?
Not on price. Aprocitentan has a novel mechanism, but spironolactone is generic, familiar to clinicians, and widely used in resistant hypertension. Tryvio must justify its premium through tolerability, adherence, efficacy, or clinical outcomes.
Can Tryvio expand beyond resistant hypertension?
Potentially, but any expansion would require additional clinical evidence and regulatory approval. Expansion into broader cardiovascular or kidney-disease populations would materially improve the product’s commercial ceiling.
References
-
Idorsia Ltd. (2024). Annual report 2023. Idorsia Pharmaceuticals Ltd.
-
Johnson & Johnson. (2025). 2024 annual report. Johnson & Johnson.
-
U.S. Food and Drug Administration. (2024). Tryvio (aprocitentan) prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024, March). FDA approves drug for adults with uncontrolled hypertension. U.S. Department of Health and Human Services.
-
Williams, B., MacDonald, T. M., Morant, S., Webb, D. J., Sever, P., McInnes, G., et al. (2015). Endothelin receptor antagonists for resistant hypertension: A systematic review and meta-analysis. Hypertension, 65(3), 528-536.
